Serum Amyloid A: a Novel Biomarker for Endometrial Cancer

Overview

Journal Cancer

Publisher Wiley

Specialty Oncology

Date 2009 Dec 31

PMID 20041483

Citations 41

Authors

Emiliano Cocco

Stefania Bellone

Karim El-Sahwi

Marilisa Cargnelutti

Natalia Buza

Fattaneh A Tavassoli

Peter E Schwartz

Thomas J Rutherford

Sergio Pecorelli

Alessandro D Santin

Affiliations

Soon will be listed here.

Abstract

Background: The authors investigated the expression of serum amyloid A (SAA) in endometrial endometrioid carcinoma and evaluated its potential as a serum biomarker.

Methods: SAA gene and protein expression levels were evaluated in endometrial endometrioid carcinoma and normal endometrial tissues, by real-time polymerase chain reaction (PCR), immunohistochemistry (IHC), and flow cytometry. SAA concentration in 194 serum samples from 50 healthy women, 42 women with benign diseases, and 102 patients including 49 grade 1, 38 grade 2, and 15 grade 3 endometrial endometrioid carcinoma was also studied by a sensitive bead-based immunoassay.

Results: SAA gene expression levels were significantly higher in endometrial endometrioid carcinoma when compared with normal endometrial tissues (mean copy number by real-time PCR = 182 vs 1.9; P = .001). IHC revealed diffuse cytoplasmic SAA protein staining in poorly differentiated endometrial endometrioid carcinoma tissues. High intracellular levels of SAA were identified in primary endometrial endometrioid carcinoma cell lines evaluated by flow cytometry, and SAA was found to be actively secreted in vitro. SAA concentrations (microg/mL) had medians of 6.0 in normal healthy women and 6.0 in patients with benign disease (P = .92). In contrast, SAA values in the serum of endometrial endometrioid carcinoma patients had a median of 23.7, significantly higher than those of the healthy group (P = .001) and benign group (P = .001). Patients harboring G3 endometrial endometrioid carcinoma were found to have SAA concentrations significantly higher than those of G1/G2 patients.

Conclusions: SAA is not only a liver-secreted protein, but is also an endometrial endometrioid carcinoma cell product. SAA is expressed and actively secreted by G3 endometrial endometrioid carcinoma, and it is present in high concentration in the serum of endometrial endometrioid carcinoma patients. SAA may represent a novel biomarker for endometrial endometrioid carcinoma to monitor disease recurrence and response to therapy.

Citing Articles

Identification of crucial genes through WGCNA in the progression of gastric cancer.

Liu R, Liu J, Cao Q, Chu Y, Chi H, Zhang J J Cancer. 2024; 15(11):3284-3296.

PMID: 38817876 PMC: 11134444. DOI: 10.7150/jca.95757.

Plasma Proteomic Signature of Endometrial Cancer in Patients with Diabetes.

Mujammami M, Rafiullah M, Akkour K, Alfadda A, Masood A, Joy S ACS Omega. 2024; 9(4):4721-4732.

PMID: 38313512 PMC: 10831832. DOI: 10.1021/acsomega.3c07992.

Secreted proteins in plasma and placenta as novel non-invasive biomarkers for intrahepatic cholestasis of pregnancy: A case-control study.

Chen L, Li J, You Y, Qian Z, Liu J, Jiang Y Heliyon. 2023; 9(11):e21616.

PMID: 38027820 PMC: 10661505. DOI: 10.1016/j.heliyon.2023.e21616.

The Latest Developments in Using Proteomic Biomarkers from Urine and Serum for Non-Invasive Disease Diagnosis and Prognosis.

Shama A, Soni T, Jawanda I, Upadhyay G, Sharma A, Prabha V Biomark Insights. 2023; 18:11772719231190218.

PMID: 37528936 PMC: 10387783. DOI: 10.1177/11772719231190218.

SAA1 identified as a potential prediction biomarker for metastasis of hepatocellular carcinoma multi-omics approaches.

Li G, Shen Q, Xu H, Zhou Y, Li C, Li Y Front Oncol. 2023; 13:1138995.

PMID: 37081987 PMC: 10110885. DOI: 10.3389/fonc.2023.1138995.

References

Diamandis E . Identification of serum amyloid a protein as a potentially useful biomarker for nasopharyngeal carcinoma. Clin Cancer Res. 2004; 10(15):5293. DOI: 10.1158/1078-0432.CCR-04-0377. View

Tassi R, Bignotti E, Falchetti M, Calza S, Ravaggi A, Rossi E . Mammaglobin B expression in human endometrial cancer. Int J Gynecol Cancer. 2007; 18(5):1090-6. DOI: 10.1111/j.1525-1438.2007.01137.x. View

Bignotti E, Ravaggi A, Tassi R, Calza S, Rossi E, Falchetti M . Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. Br J Cancer. 2008; 99(5):768-73. PMC: 2528153. DOI: 10.1038/sj.bjc.6604546. View

Rose P . Endometrial carcinoma. N Engl J Med. 1996; 335(9):640-9. DOI: 10.1056/NEJM199608293350907. View

Santin A, Zhan F, Cane S, Bellone S, Palmieri M, Thomas M . Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer. 2005; 92(8):1561-73. PMC: 2362016. DOI: 10.1038/sj.bjc.6602480. View

Urieli-Shoval S, Cohen P, Eisenberg S, Matzner Y . Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium. J Histochem Cytochem. 1998; 46(12):1377-84. DOI: 10.1177/002215549804601206. View

Dotters D . Preoperative CA 125 in endometrial cancer: is it useful?. Am J Obstet Gynecol. 2000; 182(6):1328-34. DOI: 10.1067/mob.2000.106251. View

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T . Cancer statistics, 2008. CA Cancer J Clin. 2008; 58(2):71-96. DOI: 10.3322/CA.2007.0010. View

Cho W, Yip T, Yip C, Yip V, Thulasiraman V, Ngan R . Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res. 2004; 10(1 Pt 1):43-52. DOI: 10.1158/1078-0432.ccr-0413-3. View

10.

Urieli-Shoval S, Linke R, Matzner Y . Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol. 1999; 7(1):64-9. DOI: 10.1097/00062752-200001000-00012. View

11.

Chung H, Kim J, Park N, Song Y, Kang S, Lee H . Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol Scand. 2007; 85(12):1501-5. DOI: 10.1080/00016340601022777. View

12.

Powell J, Hill K, Shiro B, Diehl S, Gajewski W . Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med. 2005; 50(8):585-90. View

13.

Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T . Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A. 2005; 102(21):7677-82. PMC: 1140439. DOI: 10.1073/pnas.0502178102. View

14.

Yamada T . Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med. 1999; 37(4):381-8. DOI: 10.1515/CCLM.1999.063. View

15.

Chan D, Chen C, Chu H, Chang W, Yu J, Chen Y . Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann Surg Oncol. 2006; 14(1):84-93. DOI: 10.1245/s10434-006-9091-z. View

16.

Gutfeld O, Prus D, Ackerman Z, Dishon S, Linke R, Levin M . Expression of serum amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis. J Histochem Cytochem. 2005; 54(1):63-73. DOI: 10.1369/jhc.5A6645.2005. View

17.

Howard B, Wang M, Campa M, Corro C, Fitzgerald M, Patz Jr E . Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. Proteomics. 2003; 3(9):1720-4. DOI: 10.1002/pmic.200300514. View

18.

Soper J, Berchuck A, Olt G, Soisson A, Clarke-Pearson D, Bast Jr R . Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma. Am J Obstet Gynecol. 1990; 163(4 Pt 1):1204-9. DOI: 10.1016/0002-9378(90)90692-z. View

19.

Bokhman J . Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983; 15(1):10-7. DOI: 10.1016/0090-8258(83)90111-7. View

20.

Sood A, Buller R, Burger R, Dawson J, Sorosky J, Berman M . Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol. 1997; 90(3):441-7. DOI: 10.1016/s0029-7844(97)00286-x. View